Document Detail

Treatment of primary aldosteronism: Where are we now?
MedLine Citation:
PMID:  21305359     Owner:  NLM     Status:  MEDLINE    
Primary aldosteronism (PA) is an important cause of secondary hypertension, is being increasingly diagnosed and may account for more than 10% of hypertensive patients, both in primary care and in referral centers. Aldosterone excess is associated with adverse cardiovascular, renal and metabolic effects that are in part hypertension-independent. Laparoscopic adrenalectomy remains the mainstay of treatment for unilateral forms of PA, whereas medical treatment is recommended for bilateral forms of PA. However, a favourable surgical outcome depends on several factors and many patients are not suitable for this treatment. On the other hand, surgery in patients considered to have bilateral PA may contribute to better blood pressure control. In this review, established and novel strategies for the management of different types of PA are discussed.
Asterios Karagiannis
Related Documents :
16466159 - Development of a novel type of shoe to improve the efficiency of knee-ankle-foot orthos...
19964379 - Automatic actuator control by leg load signal of active afo for achilles tendon ruptures.
1523489 - Changes in endplate vascularity after an outer anulus tear in the sheep.
12472249 - Thoracolumbar spine mechanics contrasted under compression and shear loading.
21254889 - Does isotretinoin therapy have any effects on electrocardiography, heart rate and blood...
23591679 - Pediatric ambulatory blood pressure monitoring: diagnosis of hypertension.
2750809 - Uncoupling of excitation from contraction in uterine smooth muscle in near-term ewes.
9360119 - In vitro and in vivo evaluation of a left-right balancing capacity of an interatrial sh...
36049 - Influence of hydrogen ion concentration on bile acid induced acute gastric mucosal ulce...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Reviews in endocrine & metabolic disorders     Volume:  12     ISSN:  1573-2606     ISO Abbreviation:  Rev Endocr Metab Disord     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-05-03     Completed Date:  2011-09-01     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  100940588     Medline TA:  Rev Endocr Metab Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  15-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Hyperaldosteronism / diagnosis,  drug therapy*,  surgery*
Spironolactone / analogs & derivatives,  therapeutic use
Reg. No./Substance:
27O7W4T232/Spironolactone; 6995V82D0B/eplerenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary aldosteronism: A Japanese perspective.
Next Document:  Viability of cryopreserved human skin allografts: effects of transport media and cryoprotectant.